Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice
- PMID: 16243031
- DOI: 10.1016/j.cub.2005.08.066
Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice
Abstract
Many cancers possess elevated levels of PtdIns(3,4,5)P(3), the second messenger that induces activation of the protein kinases PKB/Akt and S6K and thereby stimulates cell proliferation, growth, and survival. The importance of this pathway in tumorigenesis has been highlighted by the finding that PTEN, the lipid phosphatase that breaks down PtdIns(3,4,5)P(3) to PtdIns(4,5)P(2), is frequently mutated in human cancer. Cells lacking PTEN possess elevated levels of PtdIns(3,4,5)P(3), PKB, and S6K activity and heterozygous PTEN(+/-) mice develop a variety of tumors. Knockout of PKBalpha in PTEN-deficient cells reduces aggressive growth and promotes apoptosis, whereas treatment of PTEN(+/-) mice with rapamycin, an inhibitor of the activation of S6K, reduces neoplasia. We explored the importance of PDK1, the protein kinase that activates PKB and S6K, in mediating tumorigenesis caused by the deletion of PTEN. We demonstrate that reducing the expression of PDK1 in PTEN(+/-) mice, markedly protects these animals from developing a wide range of tumors. Our findings provide genetic evidence that PDK1 is a key effector in mediating neoplasia resulting from loss of PTEN and also validate PDK1 as a promising anticancer target for the prevention of tumors that possess elevated PKB and S6K activity.
Similar articles
-
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice.Biochem J. 2008 Jun 1;412(2):211-21. doi: 10.1042/BJ20080557. Biochem J. 2008. PMID: 18387000
-
Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma.Oncogene. 2014 Aug 21;33(34):4330-9. doi: 10.1038/onc.2013.383. Epub 2013 Sep 16. Oncogene. 2014. PMID: 24037523 Free PMC article.
-
Cell type specificity of PI3K signaling in Pdk1- and Pten-deficient brains.Genes Dev. 2009 Jul 15;23(14):1619-24. doi: 10.1101/gad.1799609. Genes Dev. 2009. PMID: 19605683 Free PMC article.
-
PDK1, the master regulator of AGC kinase signal transduction.Semin Cell Dev Biol. 2004 Apr;15(2):161-70. doi: 10.1016/j.semcdb.2003.12.022. Semin Cell Dev Biol. 2004. PMID: 15209375 Review.
-
Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways.Cell Cycle. 2008 Oct;7(19):2978-82. doi: 10.4161/cc.7.19.6810. Epub 2008 Oct 18. Cell Cycle. 2008. PMID: 18802401 Review.
Cited by
-
A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.Br J Cancer. 2010 Jan 5;102(1):104-14. doi: 10.1038/sj.bjc.6605408. Br J Cancer. 2010. PMID: 20051961 Free PMC article.
-
Sprouty1 induces a senescence-associated secretory phenotype by regulating NFκB activity: implications for tumorigenesis.Cell Death Differ. 2014 Feb;21(2):333-43. doi: 10.1038/cdd.2013.161. Epub 2013 Nov 22. Cell Death Differ. 2014. PMID: 24270409 Free PMC article.
-
Multiple implications of 3-phosphoinositide-dependent protein kinase 1 in human cancer.World J Biol Chem. 2010 Aug 26;1(8):239-47. doi: 10.4331/wjbc.v1.i8.239. World J Biol Chem. 2010. PMID: 21537480 Free PMC article.
-
Serine/Threonine Kinase 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1) as a Key Regulator of Cell Migration and Cancer Dissemination.Cancers (Basel). 2017 Mar 11;9(3):25. doi: 10.3390/cancers9030025. Cancers (Basel). 2017. PMID: 28287465 Free PMC article. Review.
-
3'Phosphoinositide-dependent kinase-1 is essential for ischemic preconditioning of the myocardium.FASEB J. 2006 Dec;20(14):2556-8. doi: 10.1096/fj.06-6252fje. Epub 2006 Oct 31. FASEB J. 2006. PMID: 17077284 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous